GTP cyclohydrolase I feedback regulatorGenealiases: GFRP · HsT16933 · P35
Q-omics provides the consensus-scored GCHFR profile across patient tissues and cancer cell-line models. GCHFR expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GCHFR is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, GCHFR RNA expression shows 19,242 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where GCHFR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCHFR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCHFR survival associations across molecular data types. GCHFR RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCHFR RNA expression–survival associations across cancer types. High GCHFR expression shows unfavorable associations in UVM and ACC, but favorable associations in KIRC, HNSC, MESO and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GCHFR RNA expression.
This table summarizes GCHFR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GCHFR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCHFR shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in BLCA, THCA and STAD. The BLCA box plot shows higher GCHFR RNA expression in tumor versus normal tissue (log2 FC = +1.122, t-test p < 0.001).
This table shows molecular features associated with GCHFR in patient tissues and cancer cell lines. In patient samples, GCHFR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GCHFR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BREAST.
